Palivizumab for prophylaxis of RSV infection: five epidemic seasons' experience on adverse effects (2002-2007).
Parmigiani
Stefano
S
Pezzoni
Silvia
S
Solari
Elena
E
Arena
Vittoria
V
De Martino
Arianna
A
Alessandrini
Cristina
C
Moretti
Sabrina
S
Bevilacqua
Giulio
G
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000009:adverse effects*; D001997:Bronchopulmonary Dysplasia; D018890:Chemoprevention / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab